KU-Xcell Therapeutics Collaborate on Stem Cell and Exosome Therapies 

KU Institute of Convergence Science and Technology at Konkuk University and Xcell Therapeutics announced today that they have signed a business cooperation agreement to jointly develop stem cell and exosome therapeutics using serum-free chemotactic media.

Both parties will actively share their research experiences and technologies. Based on this, KU Institute of Convergence Science and Technology expects to achieve synergistic effects in building the entire research process from planning clinical trials to applying the results. In particular, when designing the development of cellular therapeutics, it was decided to adopt serum-free chemical composition culture media from the preclinical stage.

It also plans to advance the research on 'Development of efficient in vivo cell conversion technology for the treatment of intractable bladder diseases', which is being conducted by the Department of Stem Cell Regeneration Engineering and Molecular Cell Programming Center of KU Convergence Science and Technology.

Xcell Therapeutics says it has various cell culture manufacturing technologies, including serum-free chemotactic culture media for mesenchymal stem cells. The company has an annual production capacity of 100,000 liters of culture medium through a production facility completed in Yongin last year.

"Through this partnership, we hope that the importance of adopting chemotactic media that can demonstrate 100% stability in preparation for cell therapy development will be widely recognized," said Dr. Yi Il Lee, CEO of Xcell Therapeutics.

Source: https://www.hankyung.com/it/article/202011183568i